Curaleaf (OTCMKTS:CURLF) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Curaleaf (OTCMKTS:CURLF) from a strong sell rating to a hold rating in a research report released on Thursday,Zacks.com reports.

Other research analysts also recently issued research reports about the company. Atb Cap Markets raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. ATB Capital raised shares of Curaleaf to an “outperform” rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group upgraded shares of Curaleaf to a “strong-buy” rating in a report on Thursday, October 9th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Curaleaf in a research note on Monday, December 22nd. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Curaleaf presently has an average rating of “Buy”.

Curaleaf Stock Up 4.0%

Shares of OTCMKTS:CURLF opened at $2.62 on Thursday. Curaleaf has a 52-week low of $0.68 and a 52-week high of $5.05. The company has a market capitalization of $1.78 billion, a PE ratio of -8.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.71 and a current ratio of 1.47. The company has a fifty day moving average of $2.69 and a 200-day moving average of $2.35.

Curaleaf (OTCMKTS:CURLF) last issued its earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. On average, equities analysts predict that Curaleaf will post -0.25 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.